• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Sentien raises $12m Series A for drug-device combo for acute kidney injury

April 4, 2017 By Sarah Faulkner

Sentien raises $12m Series A for drug-device combo for acute kidney injurySentien Biotechnologies said today that it closed a $12 million Series A financing round, co-led by Boehringer-Ingelheim Venture Fund USA, Inc. and BioInnovation Capital. Chiesi Ventures, MBL Venture Capital Co. and Mass Medical Angels also contributed to the round.

The Cambridge, Mass.-based company said it plans to use the funds for initial clinical development of its drug-device combination product, SBI-101.

Sentien’s SBI-101 combines mesenchymal stromal cells with an approved blood-filtration device, which delivers MSC-secreted factors in a controlled, sustained manner to treat acute kidney injury

The company said that its product has a longer duration of cellular therapeutic activity compared to traditional cell therapy.

“Sentien has made remarkable progress in the short period of time since our seed investment and is ready to advance its first product, SBI-101, into the clinic,” BIVF, USA managing director Martin Heidecker said in prepared remarks. “We are excited to build on this momentum, along with the other leading investors in this Series A financing.”

“Sentien brings a skilled team and unique approach to regenerative medicine,” Dr. Johannes Fruehauf, general partner of BioInnovation Capital, added. “We look forward to working with Sentien to support its first clinical program and prepare the company for accelerated growth.”

Fruehauf and Giacomo Chiesi will join Sentien’s board of directors in connection with the round, according to Sentien.

“We are excited to have the support of such an accomplished group of investors,” CEO Brian Miller said. “We are now poised to move our lead product into the clinic, where we have the opportunity to treat AKI, a significant unmet medical need, and to continue to develop new applications for our novel approach to cell therapy.”

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Funding Roundup, Wall Street Beat Tagged With: Sentien Biotechnologies

IN CASE YOU MISSED IT

  • Rapid Dose closes first tranche of $5M financing
  • Senseonics stock is up as it sticks by revenue guidance
  • MedAlliance wins second FDA IDE nod for drug-coated balloon
  • Wells Fargo downgrades Tandem amid rise of automated insulin delivery competition
  • FDA approves first targeted infusion therapy for HER2-low breast cancer

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS